BCR::ABL1单核酸变体对阿西米尼布疗效的影响
Andrew J Innes1,2, Chloe Hayden3, Victoria Orovboni3
1Centre for Haematology, Faculty of Medicine, Imperial College London, London, United Kingdom. a.innes@imperial.ac.uk.
Leukemia
|September 19, 2024
概括
阿西米尼布是一种BCR::ABL1抑制剂,在慢性髓性白血病患者中表现出良好的耐受性和疗效. 大多数患者继续接受治疗,获得显著的细胞遗传反应,不耐受是停止治疗的关键原因.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 血液学 血液学 血液学
背景情况:
- 阿西米尼布是一种针对BCR::ABL1阳性恶性瘤的向治疗.
- 选择性BCR::ABL1抑制可以减少目标外毒性.
- 了解治疗反应和耐药性机制至关重要.
研究的目的:
- 评估阿西米尼布在受管理访问计划治疗的患者中的毒性和反应.
- 调查治疗停止的原因.
- 探索 BCR::ABL1 单核酸变体 (BSNV) 在治疗结果中的作用.
主要方法:
- 对49名接受阿斯基米尼布治疗的患者进行了回顾性分析.
- 评估治疗毒性,反应 (完全细胞遗传反应或更好),以及停止治疗的原因.
- 下一代测序用于BSNVs的串行跟踪.
主要成果:
- 阿西米尼布耐受性良好,大多数患者在14个月的中位随访期继续接受治疗 (59%).
- 治疗停止后,不耐受性 (65%) 比耐药性 (35%) 更常见.
- 66%的可评估患者实现了完整的细胞遗传反应或更好.
- 在以前患有非T315I-BSNVs的患者中观察到较差的反应.
- 观察到BSNV寄存种群的克隆扩张,与强化剂量的耐药性或反应有关.
结论:
- 阿西米尼布在现实环境中表现出良好的耐受性和有效性.
- 不耐受性是中止治疗的一个重要因素.
- BSNVs影响治疗反应,可能需要剂量调整以获得最佳结果.
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K